Related Articles
A novel NF‑κB inhibitor, DHMEQ, ameliorates pristane‑induced lupus in mice
miR‑101‑3p negatively regulates inflammation in systemic lupus erythematosus via MAPK1 targeting and inhibition of the NF‑κB pathway
4‑phenylbutyric acid mediates therapeutic effect in systemic lupus erythematosus: Observations in an experimental murine lupus model
Interleukin-12 exacerbates symptoms in an MRL/MpJ-Faslpr mouse model of systemic lupus erythematosus
Association of the osteopontin rs1126616 polymorphism and a higher serum osteopontin level with lupus nephritis